# Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Source: https://onco.cc/trials/nct05594797/  
OnCo record `nct05594797` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Human BCMA Targeted T Cells Injection in multiple myeloma, run by Hrain Biotechnology Co., Ltd., now recruiting.

## Summary

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM is a phase 2 interventional study registered as NCT05594797 by Hrain Biotechnology Co., Ltd., with 100 participants planned, started 2022-07-12 and due to reach its primary completion in 2025-07-31. Interventions recorded: Human BCMA Targeted T Cells Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05594797
- Phase: 2
- Setting: A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection Therapy for Relapsed/Refractory Multiple Myeloma
- Sponsor: Hrain Biotechnology Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05594797: https://clinicaltrials.gov/study/NCT05594797

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)

---
JSON: https://onco.cc/api/v1/entities/nct05594797.json